Recruiting
Phase 1

INCB161734

Sponsor:

Incyte Corporation

Code:

NCT07853040

Conditions

Hepatic Insufficiency

Liver Diseases

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

INCB161734

Study Details

Brief summary:

This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.

Conditions

Hepatic Insufficiency

Liver Diseases

Study ID

NCT07853040

Start date

Oct 27, 2026

Status verified date

Nov, 2026

Completion date

Mar 31, 2027

Anticipated

Primary completion date

Mar 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Age 18 to 80 years (inclusive) at the time of signing the ICF.
  • Moderate or severe hepatic impairment based on Child-Pugh score.
  • Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory examinations at screening and check-in.
  • BMI of 18.0 to 44.0 kg/m2 (inclusive) at screening.
  • Ability to swallow and retain oral tablets.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • In the opinion of the investigator, history of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months before screening or evidence of rapidly deteriorating hepatic function.
  • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study.
  • Current, functioning organ transplant or on the national transplant list and expected to receive a transplant within 3 months.
  • History of an autoimmune disease diagnosis (eg, myasthenia gravis).
  • History of malignancy within 5 years before screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • History of clinically significant GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
  • Severe ascites (ascites requiring paracentesis more than twice every 4 weeks) or encephalopathy ≥ Grade 2 (precludes them from understanding and signing an ICF).
  • Any major surgery within 4 weeks before screening.
  • Donation of blood within 4 weeks before screening (within 2 weeks for plasma only).
  • Blood transfusion within 4 weeks before check-in (Day -1).
  • Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics or current clinically significant viral infection at screening or check-in (Day -1).
  • History of alcoholism within 3 months before screening.
  • Positive breath, urine, or blood test for ethanol or positive serum or urine screen for drugs of abuse that is not otherwise explained by permitted concomitant medications.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before study drug administration with another investigational medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before study drug administration with an inducer or inhibitor of CYP3A4, P-gp, or BCRP.
  • Use of prescription drugs (including hormonal contraceptives) within 14 days before study drug administration or nonprescription medications/products (including megadose vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations as well as pre/probiotics) within 7 days before study drug administration.

  • Note 1: Occasional acetaminophen, standard-dose ibuprofen, and standard-dose vitamins are permitted.
  • Note 2: Established therapy for hepatic disease, or the treatment of associated disorders, that has been stable for at least 7 days prior to study drug administration is allowed if approved by the medical monitor and investigator.
  • Consumption of alcohol within 1 month before screening.
  • Consumption of caffeine-containing foods and beverages within 3 days before check-in (Day -1).
  • Consumption of Seville oranges, grapefruits, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 7 days before the first dose of study drug.
  • Current use of prohibited medication.
  • Receipt of live (including attenuated) vaccines or anticipation of need for such a vaccine during the study. (Note: Non-live or inactivated vaccines allowed up to 2 weeks before study drug administration.).
  • Known hypersensitivity or severe reaction to INCB161734 or excipients of INCB161734.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Inability to undergo venipuncture or tolerate venous access.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of the study data.
  • Currently smoke > 10 cigarettes per day, or equivalent use of other tobacco- or nicotine-containing products, and are unwilling to refrain from tobacco or nicotine use on treatment days and abide by CRU restrictions.
  • Women who are pregnant or breastfeeding.
  • New medication requirement or an increase in dose for hepatic encephalopathy within 3 months prior to check-in.
  • Current portal systemic shunt.
  • Esophageal banding within 3 months prior to check-in or required any other treatment for GI bleeding within 6 months prior to check-in. Hemorrhoidal banding is permitted.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Design

Enrollment

24 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Cohort 1: Moderate hepatic impairment

Participants with moderate hepatic impairment will be enrolled in Cohort 1.

experimental: Cohort 2: Severe hepatic impairment

Participants with severe hepatic impairment will be enrolled in Cohort 2.

Interventions

INCB161734

single dose administered orally

Primary outcome measure

  • PK for plasma INCB161734: Cmax [ Time Frame: Up to approximately 1.5 months ]
  • PK for plasma INCB161734: AUClast [ Time Frame: Up to approximately 1.5 months ]
  • PK for plasma INCB161734: AUCinf [ Time Frame: Up to approximately 1.5 months ]

Central Contacts and Locations

Central contacts

Incyte Corporation Call Center (US)

1.855.463.3463medinfo@incyte.com

Incyte Corporation Call Center (ex-US)

+800 00027423eumedinfo@incyte.com

Locations

Arizona Clinical Trials - the Institute For Liver Health

Recruiting

Chandler, Arizona, United States, 85225

Orlando Clinical Research Center

Recruiting

Orlando, Florida, United States, 32809

Texas Liver Institute - American Research Corporation

Recruiting

San Antonio, Texas, United States, 78215

More Information

Sponsor

Incyte Corporation

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • hepatic impairment
  • liver impairment (moderate and severe)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.